The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 649-655

  Dodds, Helen M ^a   Tobin, Peter J ^b   Stewart, Clinton F ^c   Cheshire, Pam ^c   Hanna, Suzan ^c   Houghton, Peter ^a   Rivory, Laurent P ^c  

^a University of Sydney   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; DNA TOPOISOMERASE INHIBITOR; ESTERASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; DRUG ACTIVATION; DRUG TUMOR LEVEL; FEMALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TIME; TUMOR XENOGRAFT;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; BRAIN NEOPLASMS; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUCURONIDASE; HUMANS; KINETICS; MICE; MICE, SCID; MICRODIALYSIS; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036827597     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039040     Document Type: Article

References (36)

1. Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, and Gupta E (1999) In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res 19:2067-2071.
2. Atsumi R, Okazaki O, and Hakusui H (1995) Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol Pharm Bull 18:1024-1026.
3. Azoulay M, Florent JC, Monneret C, Gesson JP, Jacquesy JC, Tillequin F, Koch M, Bosslet K, Czech J, and Hoffman D (1995) Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anticancer Drug Des 10:-441-450.
4. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, and Monneret C (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58:1195-1201.
5. Dodds HM, Clarke SJ, Findlay M, Bishop JF, Robert J, and Rivory LP (2000) Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemother Pharmacol 45:9-14.
6. Dodds HM, Craik DJ, and Rivory LP (1997) Photodegradation ofirinotecan (CPT-11) in aqueous solutions: Identification of fluorescent products and influence of solution composition. J Pharm Sci 86:1410 -1416.
7. Guemei AA, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov MV, Grem JL, Ismail AS, Bowen D, Taylor RE, et al. (2001) Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: Correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother Pharmacol 47:283-290.
8. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R, and Canal P (1999) CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 80:364-370.
9. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. J Pharmacol Exp Ther 73:147-171.
10. Johnson DH (2001) Irinotecan: Summary and future directions. Oncology 15:46-47.
11. Kaneda N, Nagata H, Furuta T, and Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720.
12. Kaneda N and Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725.
13. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
14. Kojima A, Hackett NR, and Crystal RG (1998) Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res 58:4368-4374.
15. Kono A and Hara Y (1991) [Conversion of CPT-11 into SN-38 in human tissues]. Gan To Kagaku Ryoho 18:2175-2178.
16. Lavrijsen K, van Houdt J, van Dyck D, Hendrickx J, Bockx M, Hurkmans R, Meuldermans W, Le Jeune L, Lauwers W, and Heykants J (1992) Comparative metabolism of flunarizine in rats, dogs and man: An in vitro study with subcellular liver fractions and isolated hepatocytes. Xenobiotica 22:815-836.
17. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Miyauchi S, Sugiyama Y, Iga T, and Hanano M (1989) The conjugative metabolism of 4-methylumbelliferone and deconjugation to the parent drug examined by isolated perfused liver and in vitro liver homogenate of rats. Chem Pharm Bull 37:475-480.
19. Murdter TE, Sperker B, Kivisto KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, and Kroemer HK (1997) Enhanced uptake of doxorubicin into bronchial adenocarcinoma: β-glucunidase mediates release of doxorubicin from glucuronade prodrug (HMR 1826) at the tumor site. Cancer Res 57:2440-2445.
20. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, and Kamataki T (1993) Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5-10.
21. Rivory LP, Bowles MR, Robert J, and Pond SM (1996a) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111.
22. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, Pond SM, and Robert J (1996b) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694.
23. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11 and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661:133-141.
24. Rowland M and Tozer TN (1989) Clinical Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia.
25. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
26. Senter PD, Marquardt H, Thomas BA, Hammock BD, Frank IS, and Svensson HP (1996) The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res 56:1471-1474.
27. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, and Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747-2754.
28. Sperker B, Werner U, Murdter TE, Tekkaya C, Fritz P, Wacke R, Adam U, Gerken M, Drewelow B, and Kroemer HK (2000) Expression and function of β-glucuronidase in pancreatic cancer: Potential role in drug targeting. Naunyn Schmiedebergs' Arch Pharmacol 362:110-115.
29. Stewart CF, Zamboni WC, Crom WR, and Houghton PJ (1997) Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40:259-265.
30. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757.
31. Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, and Houghton PJ (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8:313-322.
32. Tsai MC and Gorrod JW (1999) Evidence for the biosynthesis of a glucuronide conjugate of (S)-(-)-nicotine, but not (S)-(-)-cotinine or (+/-)-trans-3′-hydroxycotinine by marmoset hepatic microsomes. Drug Metab Drug Interact 15:223-237.
33. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, and Tsuru D (1991) CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 14:341-349.
34. van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, Boven E, and Giaccone G (1998) Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 77:2171-2176.
35. Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, and Stewart CF (1998a) Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 4:455-462.
36. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, and Houghton PJ (1998b) Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4:743-753.